RankAlpha logo
Back to Rankings

KPTI

Karyopharm TherapeuticsC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
View Chart
Current thesis
The constructive read is that KPTI still has two meaningful 2026 shots on goal: more detailed SENTRY data at ASCO on June 2, 2026 and the mid-2026 XPORT-EC-042 readout, while the March financing bought enough time to reach those milestones [#PR-2026-04-21] [#8-K-2026-03-27].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +25.6.
What can break
Liquidity guidance still points only into late Q3 2026 even after the March financing, keeping dilution, debt amendment, partnering or other capital actions in play [#8-K-2026-03-27].
Momentum
58
Value
41
Sentiment
53
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.50 · Bull $14.50 · Bear $4.50
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-03 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $15.00
Why
Momentum58 · Δ7d -23.9
Value41 · Δ7d +0.1
Sentiment53 · Δ7d +25.6
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
58
26% active weight
Current posture
7d trendSoftening
Δ7d
-23.9
Δ21d
-13.4
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
53
34% active weight
Current posture
7d trendImproving
Δ7d
+25.6
Δ21d
+24.5
Why this grade

Composite grade C. Momentum 57.6 / Value 41.1 / Sentiment 53.4

Fundamentals (TTM)
As of 2026-07-20
Market Cap
$169.29M
Beta
0.21
Shares Out
22.66M
P/E (TTM) · Derived
-0.4
P/S (TTM)
0.89
P/FCF (TTM) · Derived
-1.69
Rev YoY
+16.8%
EPS YoY
-55.4%
Gross Margin
+95.9%
Op Margin
-73.1%
Net Debt
$169.86M
Current Ratio
1.08
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology